Brief: Jasper Therapeutics Announces Ind Clearance For Phase 1B/2A Study Of Subcutaneous Briquilimab In Chronic Spontaneous Urticaria
09/10/2023 13:20
Oct 9 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES IND CLEARANCE FOR PHASE
1B/2A
STUDY OF SUBCUTANEOUS BRIQUILIMAB IN CHRONIC SPONTANEOUS
URTICARIA
* JASPER THERAPEUTICS INC - CLINICAL STUDY IN CHRONIC
INDUCIBLE
URTICARIA PLANNED TO COMMENCE IN EARLY 2024
* JASPER THERAPEUTICS INC - FIRST PATIENT EXPECTED TO BE
DOSED BY
YEAR-END 2023; EARLY DATA EXPECTED BY MID-2024
Source text for Eikon: ID:nGNXMnMRf
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma